Imunon, Inc.
IMNNAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Apr 17, 2026 | Maxim Group | $10.00(+214%) | $3.18 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| D. Boral Capital | downgrade | Buy →Hold | May 19, 2025 |
| D. Boral Capital | maintain | Buy | May 13, 2025 |
| D. Boral Capital | maintain | Buy | May 7, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 26, 2025 |
| D. Boral Capital | maintain | Buy | Mar 24, 2025 |
| D. Boral Capital | maintain | Buy | Feb 27, 2025 |
| D. Boral Capital | maintain | Buy | Feb 19, 2025 |
| D. Boral Capital | maintain | Buy | Jan 24, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 19, 2024 |
| D. Boral Capital | maintain | Buy | Dec 19, 2024 |
| HC Wainwright & Co. | maintain | Buy | Dec 11, 2024 |
| D. Boral Capital | maintain | Buy | Dec 10, 2024 |
| D. Boral Capital | maintain | Buy | Nov 25, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 11, 2024 |
| EF Hutton | maintain | Buy | Nov 7, 2024 |
| EF Hutton | maintain | Buy | Oct 31, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 5, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 1, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 13, 2024 |
| HC Wainwright & Co. | maintain | Buy | Sep 15, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 11, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 12, 2023 |
| Alliance Global Partners | maintain | Buy | Oct 13, 2022 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.61| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 11, 2026 | $-0.54 | $-0.87 | — | — |
| May 12, 2026 | $-0.84 | $-1.22 | — | — |
| Mar 31, 2026 | $-1.29 | $-1.43 | — | — |
| Nov 13, 2025 | $-1.16 | $-1.20 | — | — |
| Aug 5, 2025 | $-1.87 | $-3.09 | — | — |
| May 12, 2025 | $-3.65 | $-4.56 | — | — |
| Feb 27, 2025 | $-3.26 | $-4.69 | — | $125.0K |
| Nov 7, 2024 | $-4.43 | $-4.82 | — | $125.0K |
News
Analysis of paired patient biopsies from the randomized Phase 2 OVATION 2 study shows IMNN-001 increased CD8+/Treg, CD8+/CD4+ and CD8+/IDO+ ratios in both tumor and stroma
LAWRENCEVILLE, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company will host a conference call at 11:00 a.m.
Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial
LAWRENCEVILLE, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that Stacy Lindborg, Ph.D.
Unique investment vehicle provides efficient access to equity capitalOutstanding debt of the original Note lowered by approximately 43% No issuance of common stock or dilutive warrants LAWRENCEVILLE, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), (“IMUNON” or the “Company”), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that it has entered into an Exchange Agreement, under which $1.2 million of outstanding debt, together wi…
2026 R&D Day presentation highlights include: Review of final Randomized Phase 2 overall survival results Supportive Preliminary MRD Study Data and translational findings Pathway to confirmatory readout in OVATION 3 Testimonial conversation with an OVATION 1 participant now 10 years from diagnosis LAWRENCEVILLE, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today is presenting an update on its…
Imunon, Inc. (IMNN) Shareholder/Analyst Call Transcript
Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to date
Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indications and combination regimens
Investors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ET LAWRENCEVILLE, N.J.
Leading oncology experts and company management will discuss the Phase 3 OVATION 3 study, supporting science and data, clinical progress, and upcoming milestones
Imunon, Inc. (IMNN) Q2 2026 Earnings Call Transcript